Results 21 to 30 of about 148,561 (252)
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]
, 2010 <p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Wahlgren, N. +32 more
core +1 more source
International Journal of Gerontology, 2018 Summary: Background: This study aims to measure platelet aggregation with thromboelastography (TEG) and observe low response to clopidogrel in patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy.
Lijia Zhao +3 more
doaj +1 more source
Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study
Annals of Saudi Medicine, 2019 BACKGROUND: Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI). OBJECTIVE: Investigate the impact of concomitant prescription of clopidogrel and PPI
Rahaf A. Alghamdi +4 more
doaj +1 more source
Swiss Medical Weekly, 2012 BACKGROUND: Patients who have acute coronary syndromes with or without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy of early clopidogrel administration (300 mg) (
Jean Christophe Stauffer +5 more
doaj +1 more source
Brazilian Journal of Cardiovascular SurgeryIntroduction: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. Objective: Identify predictors of clopidogrel following CABG.
Paulo Roberto L. Prates +9 more
doaj +1 more source
BMC Cardiovascular Disorders, 2022 Backgrounds Remarkable interindividual variability in clopidogrel response is observed, genetic polymorphisms in P2RY12 and its signal pathway is supposed to affect clopidogrel response in CHD patients.
Yan-Jiao Zhang +6 more
doaj +1 more source
The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial [PDF]
, 2006 <p><b>Background and Purpose:</b> The CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial proved the effectiveness of the combination of clopidogrel and aspirin compared with aspirin alone in ...
Ritter, M.A. +9 more
core +1 more source
, 2011 Objective: This study was conducted to compare the risk of recurrent hospitalization for major gastrointestinal (GI) complications (peptic ulcer, bleeding, and perforation) in patients at high GI risk who require ongoing antiplatelet therapy (aspirin ...
蕭斐元;蔡憶文;黃文鴻;溫有汶;陳珮芬;郭耿南 +1 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Introduction/Objective Acute intracranial stenting during endovascular thrombectomy (EVT) for ischemic stroke requires intraprocedural antiplatelet therapy (APT) to maintain patency. However, the hemorrhagic risk of combining APT with intravenous thrombolysis (IVT) remains uncertain.
Aaron Rodriguez‐Calienes +75 more
wiley +1 more source
Clopidogrel in Orthopaedic patients: a review of current practice in Scotland
Thrombosis Journal, 2007 Background Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively.
Bramley Diane +2 more
doaj +1 more source